×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Yahoo Finance
Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online...
1 day ago
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy
The Globe and Mail
Detailed price information for Kiora Pharmaceuticals Inc. (KPRX-Q) from The Globe and Mail including charting and trades.
1 day ago
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain ...
Yahoo Finance
Previously released ABACUS-1 clinical trial results reported KIO-301, a small molecule photoswitch, is safe, tolerable, and improved vision...
3 days ago
Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?
InvestorPlace
Kiora Pharmaceuticals stock is rising higher on Thursday as KPRX investors react to a new $45 million private placement.
3 months ago
Kiora Pharmaceuticals CEO discusses partnership with Théa Open Innovation and pipeline updates
Ophthalmology Times
David Hutton of Ophthalmology Times talks with Brian Strem, PhD, CEO Kiora Pharmaceuticals, about their recent partnership with Théa Open...
2 months ago
KPRX Stock Quote Price and Forecast
CNN
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for...
2 months ago
Kiora Pharmaceuticals secures grant for vision test validation
Investing.com
ENCINITAS, California - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company, has been awarded a grant from the...
1 month ago
Cash-strapped eye disease biotech halves portfolio
Fierce Biotech
Kiora Pharmaceuticals is narrowing its line of sight to only two assets that tackle rare retinal diseases, while two other programs will be...
9 months ago
Kiora publishes results from study demonstrating safety, tolerability and efficacy of KIO-101 for treatment of ...
Ophthalmology Times
Kiora Pharmaceuticals Inc announced the publication of results from a Phase 1 double-masked study of KIO-101, a non-steroidal...
2 months ago
Why Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today?
InvestorPlace
Kiora Pharmaceuticals (KPRX) stock is dropping on Friday after the clinical-stage pharmaceutical company received a delisting notice.
9 months ago